Document is current

Article History

Received: 16 January 2026

Accepted: 27 May 2026

First Online: 5 June 2026

Declarations

:

: Carlos Álvarez-Fernández reports having received consulting fees, payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Merck, Pfizer, Astra-Zeneca, and Bayer; and support for attending meetings and/or travel from Ipsen, Roche, and Pfizer. Urbano Anido- Herranz reports having received consulting fees, payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Merck, Ipsen, MSD, Roche, Astra-Zeneca, Janssen, Bayer, BMS and Novartis; support for attending meetings and/or travel from MSD, Ipsen, Novartis, Roche, Rovi and BMS; and having participated in Advisory Board for Pfizer. Cristina Azpitarte Raposeiras reports having received honoraria for presentations, speakers´ bureaus from BMS, Merck, Takeda, Janssen, AstraZeneca, Roche, Lilly, Bayer, MSD and Ipsen; support for attending meetings and/or travel from Roche, MSD, Lilly, Ipsen, AstraZeneca, Takeda and Bayer. Javier Casas-Nebra reports having received consulting fees, payment or honoraria for presentations, speakers or educational events from Astellas, Johnson&Johnson, Bayer; support for attending meetings and/or travel from Bayer, Johnson & Johnson; and having participated in an Advisory Board for AstraZeneca and Pfizer. Emilio Esteban-González reports financial support to participate, travel, and attend the 2024 Cambados annual meeting. Ovidio Fernández Calvo reports having received consulting fees, payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Astellas, Bayer Bristol-Myers Squibb, Ipsen, Novartis and Roche; support for attending meetings and/or travel from Astellas, Bristol-Myers Squibb and Ipsen; and having participated in a Data Safety Monitoring Board or Advisory Board for Astellas, Bristol- Myers Squibb, Eisai, Merck, and Pfizer. Natalia Fernández Núñez reports having received consulting fees, payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Pfizer, Ipsen, Roche, BMS, Bayer, Astra-Zéneca, MSD, and Lilly; support for attending meetings and/or travel from Pfizer, Ipsen, Roche, BMS, Bayer, Astra Z.neca, MSD, and Lilly; and having participated in a Data Safety Monitoring Board or Advisory Board for Pfizer. Alicia Folgar-Torres reports having received consulting fees, payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Johnson &Johnson, Ipsen; support for attending meetings and/or travel from Astellas, Janssen, Kyowa Kirin and GP-Pharm. Enrique Gallardo reports having received consulting fees, payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Astellas, Janssen, Sanofi, Bayer, Ipsen, Pfizer, Roche, BMS, MSD, Rovi, Daiichi Sankyo, Leo Pharma, Eisai, Boehringer Ingelheim, Merck, Recordati, Lilly, Advanced Accelerator Applications and GSK; support for attending meetings and/or travel from Astellas, AstraZeneca, Bayer, BMS, Eisai, Ipsen, Janssen, Leo Pharma, Pfizer, Roche, Recordati and MSD.; and having participated in a Data Safety Monitoring Board or Advisory Board forJanssen, Astellas, Bayer, Ipsen, Pfizer, Roche, Eisai, Recordati, BMS, MSD, AstraZeneca, Merck, Lilly, GSK, Advanced Accelerator Applications. Carme García Lorenzo reports having received payment or honoraria for speaker, travel, or accommodation for attending meetings from Merck, Ipsen, Bayer, Astellas, BMS, MSD, Janssen. Aránzazu González del Alba has received research funding from AstraZeneca, travel grants from AstraZeneca, Bayer, Recordati, Ipsen, Merck, MSD and Roche, and honoraria for speaker engagements, advisory boards, medical writing and continuous medical education from Advanced Accelerator Applications, Astellas, AstraZeneca, Bayer, BMS, Casen Recordati, Eisai, EUSA Pharma, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer Roche and Veracyte. Martín Lázaro-Quintela reports having received consulting fees, payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Merck, Ipsen, MSD, Lilly, Roche, Astra-Zeneca, Janssen, Regeneron, Bayer, BMS and Novartis; support for attending meetings and/or travel from MSD, Ipsen, Takeda, Roche and BMS; and having participated in a Data Safety Monitoring Board or Advisory Board for Pfizer, Merck, Astellas, Bayer, Telix, BMS and Novartis. David Lorente reports having received consulting fees, payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Janssen, Astellas, Pfizer, Bayer, BMS and Astra Zeneca; and support for attending meetings and/or travel from Janssen, Astellas, Bayer and Pfizer. María José Méndez-Vidal reports having received consulting fees, payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Merck, Ipsen, MSD, Astra-Zeneca, Janssen, Bayer, BMS and Novartis; support for attending meetings and/or travel from, Ipsen, Jassen, Recordati Rare Diseases and BMS; and having participated in an Advisory Board for Ipsen, Astra Zeneca, Janssen, Pfizer, Astellas, Telix, BMS and Novartis. Aurea Molina Díaz reports having received consulting fees, payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Merck, Ipsen, Eisai, Grünenthal Pharma, Kyowa Kirirn, Phamamar, BMS and Roche; support for attending meetings and/or travel from Pfizer, BMS, MSD, Eisai, Kyowa Kirirn, Mark, Pharmamar, AstraZeneca, Lilly, Sanofi, Takeda, Astellas, Roche, Pierre Fabre and Servier; and having participated in Advisory Board for Bayer, Pfizer, BMS, MSD, Eisai, Pierre Fabre, Pharmamar, Pfizer, Merck, Astellas, Recordati, deciphera and Novocure. Ignacio Peláez Fernández reports having received consulting fees, payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Astellas, Bayer, Merck, Ipsen. BMS, Roche, Pfizer, Astra Zeneca and Novartis. Support for attending meetings and/or travel from, Ipsen, Pfizer and Merck; and having participated in an Advisory Board for Ipsen, Astra Zeneca, Pfizer and Astellas. Daniel Pérez-Fentes reports having received consulting fees, payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Astellas, Johnson &Johnson, Bayer, Accord; support for attending meetings and/or travel from Bayer, Johnson & Johnson; and having participated in a Data Safety Monitoring Board or Advisory Board for Astellas, Bayer, Johnson & Johnson and Recordati. Ignacio Rodríguez reports having received consulting fees, payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Astellas, Johnson & Johnson, Bayer and Sanofi; and having participated in Advisory Board for Astellas, Bayer, Johnson & Johnson and GSK. Cristina Suárez reports having received research funding from BMS, Pfizer, Roche and Ipsen, consulting fees, payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Ipsen, EISAI, MSD; support for attending meetings and/or travel from Ipsen, MSD, Bayer, and having participated in Advisory Board for BMS, Pfizer, IPSEN, MSD, EUSA Ph and Tellix. Begoña P. Valderrama reports having received consulting fees, payment or honoraria for lectures, presentations, speakers’ bureaus or educational events from Astellas Pharma, Roche, Novartis AAA, Astra-Zeneca, Bayer, Bristol-Myers-Squibb, Merck, MSD, Pfizer, Ipsen, Janssen and Almirall Pharma; and support for attending meetings and/or travel from Bristol-Myers-Squibb, Pfizer, Roche, Astellas Pharma, MSD, Merck and Astra-Zeneca. Sergio Vázquez Estévez reports having received consulting fees, payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Merck, Ipsen, MSD, Astra-Zeneca, Janssen, Bayer, BMS and Novartis; support for attending meetings and/or travel from, Ipsen, Bayer and Roche; and having participated in an Advisory Board for Ipsen, Astra Zeneca, Janssen, Pfizer, Astellas, BMS, Bayer and Novartis.

: Not applicable.

: Not applicable.

: Not applicable.